Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9775447 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9775445 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9773163 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9773146 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9773120 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9775474 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9593609 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9773138 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9773238 | 1.00 | ACE (0.77) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9773177 | 0.98 | ACE (0.73) | ACEMEN1KMT2ACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | claimed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
| US-4999370-A | ANXIOLYTIC AGENTS, INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME, NOOTROPIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | ACE 1/4885MEN1 4436/4885KMT2A 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.